schweinfurtin C | 217476-94-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: schweinfurtin C
• 英文别名: 3-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-[(E)-2-[4-[(2E)-3,7-dimethylocta-2,6-dienyl]-3,5-dihydroxyphenyl]ethenyl]benzene-1,2-diol
• CAS: 217476-94-3
• 化学式: C₃₄H₄₄O₄
• 分子量: 516.721
• InChiKey: QYQQTHNUVALYSW-BUAMIOFMSA-N

物化性质

• 沸点：
  707.6±60.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  10.3
• 重原子数：
  38
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  diethyl (4-((2E)-3,7-dimethyl-2,6-octadienyl)-3,5-bis(methoxymethoxy)benzyl)phoshonate 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.4h， 生成 schweinfurtin C
  参考文献：
  名称：

  Synthesis of Schweinfurthin C, a Geranylated Stilbene from Macaranga schweinfurthii

  摘要：

  DOI：

  10.1021/jo9908795

文献信息

• [EN] PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE COMPOSÉS HYDROXY-ARYLE ORTHO-ALLYLÉS
  申请人：UNIV MCMASTER

  公开号：WO2021237371A1

  公开（公告）日：2021-12-02

  The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (I).

  本申请描述了一种制备邻烯丙基羟基芳基化合物的方法，例如通过在非质子溶剂中，在氧化铝和铝烷氧化物中选择的铝化合物存在下，将烯丙醇与羟基芳基化合物反应，其中羟基芳基化合物中至少有一个碳原子位于羟基的邻位且未被取代。本申请还包括化合物的化学式（I）。
• SCHWEINFURTHIN ANALOGUES
  申请人：Wiemer David F.

  公开号：US20080227852A1

  公开（公告）日：2008-09-18

  Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.

  本发明涉及用于治疗癌症的对映富集的Schweinfurthin类似物的制备方法和中间体，以及具有抗癌活性的新型Schweinfurthin类似物、包含这种类似物的组合物和包括给予这种类似物的治疗方法。
• Stilbenoid prenyltransferases from plants
  申请人：Arkansas State University—Jonesboro

  公开号：US10704052B2

  公开（公告）日：2020-07-07

  The process and system led to the identification of prenyltransferase genes from elicitor-treated peanut hairy roots. One of the prenyltransferases, AhR4DT-1 catalyzes a key reaction involved in the biosynthesis of prenylated stilbenoids, in which resveratrol is prenylated at its C-4 position to form arachidin-2, while another, AhR3′DT-1, was able to add the prenyl group to C-3′ of resveratrol. Each of these prenyltransferases has a high specificity for stilbenoid substrates, and their subcellular location in the plastid was confirmed by fluorescence microscopy. Structure analysis of the prenylated stilbenoids suggest that these two prenyltransferase activities represent the first committed steps in the biosynthesis of a large number of prenylated stilbenoids and their derivatives in peanut.

  通过这一过程和系统，从诱导剂处理过的花生毛根中鉴定出了前酰转移酶基因。其中一个前酰基转移酶（AhR4DT-1）催化了参与前酰基化二苯乙烯类化合物生物合成的一个关键反应，在该反应中，白藜芦醇在其 C-4 位置被前酰基化，形成花生苷-2；而另一个前酰基转移酶（AhR3′DT-1）能够将前酰基添加到白藜芦醇的 C-3′ 位置。这些前酰基转移酶对白藜芦醇底物都有很高的特异性，荧光显微镜证实了它们在质体中的亚细胞位置。前炔基化二苯乙烯类化合物的结构分析表明，这两种前炔基化转移酶活性代表了花生中大量前炔基化二苯乙烯类化合物及其衍生物生物合成的第一步。
• STILBENOID PRENYLTRANSFERASES FROM PLANTS
  申请人：Arkansas State University-Jonesboro

  公开号：EP3472309A2

  公开（公告）日：2019-04-24
• Compounds That Bind Oxysterol Binding Proteins, and Methods of Use Thereof
  申请人：Shair Matthew D.

  公开号：US20110319352A1

  公开（公告）日：2011-12-29

  The invention relates in part to the discovery that certain CRAMs, such as schweinfurthin A, target OSBPs (a family of oxysterol binding proteins). Because OSBPs have been shown to be integral to atherosclerosis and Alzheimer's disease (AD), one aspect of the invention relates to the use of CRAMs, or a pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, in the treatment and/or prevention of atherosclerosis, Alzheimer's disease and related disorders. Another aspect of the invention relates to novel derivatives of CRAMs, or a pharmaceutically acceptable salt, biologically active metabolite, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, for the treatment and/or prevention of atherosclerosis, Alzheimer's disease and related disorders. Another aspect of the invention relates to the use of an immobilized CRAMs, such as OSW-I, to aid in screening of compounds to identify additional OSBP binders. Other aspects of the invention relate to the use of CRAMs to treat cancer, such as p21-deficient cancers.